Corcept to Resubmit Relacorilant NDA After Initial Setback

What happened

Corcept announced it will resubmit its New Drug Application for relacorilant in Cushing's syndrome, following what appears to be a complete response letter or rejection of the original submission filed in December 2024. This resubmission signals a regulatory setback that delays the potential approval timeline and introduces further uncertainty around the drug's label, manufacturing, or clinical data. While the company remains profitable with its Korlym franchise, the relacorilant catalyst is now pushed out, reducing near-term upside and increasing binary risk. The resubmission process could take several months, and the FDA's decision will hinge on the adequacy of the response to prior deficiencies. Investors must weigh the extended timeline against the company's still-solid base business but higher execution risk.

Implication

The resubmission introduces a multi-month delay and potentially higher regulatory hurdles for relacorilant, which was the primary near-term catalyst for the stock. While Corcept's existing Korlym franchise provides cash flow and profitability, the extended timeline diminishes the probability of a near-term valuation re-rating. Investors should monitor details of the resubmission, including the nature of FDA feedback and any new data required, as these will define the new PDUFA date and approval odds. The risk of a restrictive label or additional clinical trials has increased, warranting a more cautious stance. Longer-term, if resubmission succeeds, the opportunity remains intact, but the postponement weakens the bull case for the next 12 months.

Thesis delta

The previously expected FDA decision by year-end 2025 is now off the table, pushing the relacorilant catalyst into 2027 or later and increasing regulatory uncertainty. This shifts the near-term risk/reward from balanced to skewed negative, as the stock's high valuation (P/E ~73x) no longer has a clear near-term catalyst to support it. The hold/neutral stance becomes more cautious; a downgrade to underweight/seil is warranted unless the resubmission details are highly favorable.